HanchorBio Unveils Promising Preclinical Data on Innovative Fusion Protein HCB301 at SITC 2025 At the SITC 2025 conference, HanchorBio revealed groundbreaking data on HCB301, showcasing its potential in cancer immunotherapy through multi-targeting.

HanchorBio Unveils Promising Preclinical Data on Innovative Fusion Protein HCB301 at SITC 2025 #USA #Maryland #Immunotherapy #HanchorBio #HCB301

HanchorBio Accelerates Oncology Innovations with HCB101 and HCB301 Presentation Insights HanchorBio showcases their innovative immunotherapies HCB101 and HCB301, which will be presented at major oncology meetings in late 2025, demonstrating promising advancements in cancer treatment.

HanchorBio Accelerates Oncology Innovations with HCB101 and HCB301 Presentation Insights #Taiwan #Taipei #HanchorBio #HCB101 #HCB301

HanchorBio's HCB301 Abstract Accepted for Presentation at SITC 2025 Annual Meeting HanchorBio has announced that its abstract on HCB301, an innovative cancer treatment, has been accepted for a poster presentation at the SITC 2025 Annual Meeting in Maryland.

HanchorBio's HCB301 Abstract Accepted for Presentation at SITC 2025 Annual Meeting #USA #Cancer_Treatment #National_Harbor #HanchorBio #HCB301